Drug Trial Radar · NCT01769235
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: May 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,215
Actual
Start
Nov 2012
Primary completion
Sep 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior efficacy of the two active formulations over that of the vehicle in the treatment of acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%Drug
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Acanya® Gel, 1.2%/2.5%Drug
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
Vehicle of test productDrug
Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change in inflammatory lesion counts.Time frame: 12 weeks
- Mean percent change in non-inflammatory lesion counts.Time frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.